An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Trial Status: active
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and
expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R
AML) or higher-risk myelodysplastic syndrome (HR-MDS).
Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236
administered orally. Approximately 50 participants may be enrolled in Phase 1, Part 1
Dose Escalation - Monotherapy.
Phase 1, Part 2 Dose Escalation - Combination with Venetoclax will evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of
BH-30236 administered as a combination therapy with venetoclax. Approximately 48
participants may be enrolled in Phase 1, Part 2 Dose Escalation - Combination with
Venetoclax.
Phase 1b (Dose Expansion) will follow Phase 1 to further understand the relationships
among dose, exposure, toxicity, tolerability, and clinical activity. Up to 72
participants may be enrolled in Phase 1b of the study as a monotherapy or in combination
with venetoclax.
Inclusion Criteria
≥18 years.
Diagnosis of relapsed/refractory acute myelogenous leukemia (R/R) AML or higher-risk myelodysplastic syndrome (HR-MDS) with ≥5% bone marrow blast at time of inclusion.
Prior treatment history must include 1-5 prior lines of therapy.
ECOG performance status ≤2.
Adequate organ function evidenced by the following laboratory values:
Hepatic: Transaminase levels aspartate aminotransferase [AST]/ alanine transaminase [ALT] ≤ 2.5 × upper limit of normal (ULN). In cases of liver involvement by AML or MDS, AST and ALT < 5.0 × ULN is acceptable. Total bilirubin ≤ 1.5 × ULN in the absence of documented Gilbert's disease.
Renal: Measured or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula) The above are a summary, other inclusion criteria details may apply.
Exclusion Criteria
Diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia with blast crisis.
Prior allogeneic HSCT within 3 months or donor lymphocyte infusion within 30 days of start of therapy;
Active and uncontrolled infections.
Unresolved AEs greater than Grade from prior therapies.
History of other active malignancy (with certain exceptions)
Prior treatment with a CLK inhibitor.
Any acute or chronic graft versus host disease requiring systemic therapy within 4 weeks prior to study drug administration with the exception of topical steroids or the equivalent of 20 mg of prednisone or less. The above is a summary, other exclusion criteria details may apply.
Additional locations may be listed on ClinicalTrials.gov for NCT06501196.
